Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Alzheimer's Disease
Interventions
DRUG

Piromelatine 20 mg

Tablets

DRUG

Placebo

Tablets

Trial Locations (37)

10016

New York University School of Medicine, New York

11229

Integrative Clinical Trials LLC, Brooklyn

28105

AMC Research, LLC, Matthews

32159

K2 Medical Research The Villages, Lady Lake

32807

Interspond, LLC,, Orlando

33009

Velocity Clinical Research, Inc, Hallandale

33125

Verus Clinical research Corp, Miami

33126

BioMed Research Institute, Inc., Miami

33133

CCM Clinical Research Group, LLC, Miami

33134

Linfritz Research Institute Inc., Coral Gables

33135

Advance Medical Research Center, Miami

Allied Biomedical Research Institute (Clinical Trials), Miami

Vitae Research Center LLC., Miami

33137

Stein Gerontological Institute, Inc., Miami

33176

Miami Dade Medical Research Institute, Miami

33414

Alzheimer's Research and Treatment Center, Wellington

33467

Finlay Medical Research Corp., Greenacres City

33613

The University of South Florida Board of Trustees,, Tampa

34761

K2 Medical Research Winter Garden, Ocoee

38018

Neurology Clinic, P.C., Cordova

53226

Froedtert & Medical College of Wisconsin, Milwaukee

80218

The Mile High Research Center, Denver

83642

Velocity Clinical Research, Inc, Meridian

90806

Collaborative Neuroscience Research, LLC, Long Beach

90807

Asclepes Research Centers, P.C. Dba Alliance Research, Long Beach

92103

Pacific Research Network, LLC, San Diego

92626

ATP Clinical Research, Costa Mesa

92705

RAA Apex Acquisition LLC DBA Syrentis Clinical Research, Santa Ana

98007

Northwest Clinical Research Center, Bellevue

08755,

Ocean Medical Research, Jersey City

08755

Advanced Memory Research Institute of New Jersey, Toms River

02914

Rhode Island mood and memory research institute, Island Park

B3S 1N2

Centricity Research Halifax Multispecialty, Nova Scotia

N7T 4X3

Bluewater Clinical Research Group Inc, Sarnia

M4G 3E8

LMC Clinical Research Inc. d.b.a. Centricity Research, Toronto

V1Y 1Z9

OCT Research ULC (dba Okanagan Clinical Trials), Kelowna

V7T 1C5

Medical Arts Health Research Group, Vancouver

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT05267535 - Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease | Biotech Hunter | Biotech Hunter